Hepatitis News : China Approves World’s First Hepatitis E Vaccine
A Smart + Strong Site
Subscribe to:
Hep Magazine In Bulk
Hep Newsletter
Join Us:

Back to home » Hepatitis News » January 2012


emailprint

January 11, 2012

China Approves World’s First Hepatitis E Vaccine

The world’s first vaccine against hepatitis E virus (HEV) has been approved by Chinese health authorities, according to ChinaDaily.com. The approval of the three-dose vaccine, called Hecelon (HEV 239), follows encouraging results from a study reported in an August 2011 issue of The Lancet suggesting an efficacy rate of 100 percent.

Like hepatitis A virus (HAV), HEV can lead to serious illness during the acute stage of infection—up to 3 percent of the general population and up to 25 percent of pregnant women can die of the disease—but does not lead to chronic infection. While rare in the United States, Hepatitis E is common in many parts of the world.

HEV is usually transmitted by ingesting food and liquid contaminated with fecal matter—even in microscopic amounts. Outbreaks are usually associated with contaminated water supply in countries with poor sanitation.

Until now, a vaccine has not been available anywhere in the world. But with approval of Hecelon, developed by Xiamen Innovax Biotech and researchers Xiamen University in southeast China's Fujian province, the rollout of a highly effective vaccine is set to begin.

According to the August 22 paper published in The Lancet, the Xiamen’s pivotal Phase III trial enrolled 97,356 healthy residents of China’s coastal province of Jiangsu. None had been infected with HEV in the past.

Roughly half of the study subjects received Hecelon—administered once at the beginning of the trial, with a second injection administered a month later and a third injection administered six months after the first—and have were given placebo injections.

Within a year after the injections were completed, the vaccine proved completely effective among those who received active injections. In contrast, there were 15 cases of hepatitis E among study subjects in the placebo group.

Of note, the vaccine efficacy was equally high when the analysis was expanded to include participants who only got two doses and reached 95.5 percent among those who got at least one dose.

The approval of Hecelon was announced Wednesday, January 11, by China’s Ministry of Science and Technology. Additional information regarding rollout plans or potential approval and distribution in other countries was not provided.

Search: Hecelon, HEV 239, Xiamen Innovax Biotech, Xiamen University, China, Jiangsu, Lancet, hepatitis E, vaccine, prevention


Scroll down to comment on this story. Click here to visit the Hep Forums and ask questions about this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The Hep team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (0 total)


[Go to top]

Quick Links
Current Issue
Forums
Poll
Blogs
Hep TV
Calendar
Services Directory
Conference News
Top Stories
Treatment News
Hep Exclusives
All About Hepatitis
• Hepatitis A
Transmission
Prevention
Treatment
• Hepatitis B
Transmission
Prevention
Treatment
• Hepatitis C
Transmission
Prevention
Treatment
HCV/HIV Coinfection
Help Paying For Meds
Clinical Trials
TALK TO US
Tell us what you think
Poll
Should Medicaid limit access to new hep C drugs?
Yes
No


Survey
Hepatitis C Reader Survey
HEP ON TWITTER
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.